Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Batool Shafaghi"'
Autor:
Akram Ansarifar, Ramin Hamidi Farahani, Ahmad Karimi Rahjerdi, Mohammadreza Ahi, Ali Sheidaei, Kimiya Gohari, Zahra Rahimi, Fatemeh Gholami, Pouria Basiri, Milad Moradi, Arash Jahangiri, Kosar Naderi, Soheil Ghasemi, Pezhman Khatami, Mohsen Honari, Samane Khodaverdloo, Mohammad Shooshtari, Hajar Mehr Azin, Sohrab Moradi, Batool Shafaghi, Hossein Allahyari, Arina Monazah, Ali Khodaei Poor, Hooman Bakhshande, Zahra Taghva, Mohammad Karimi Nia, Masoud Solaymani Dodaran, Mohsen Foroughizadeh
Publikováno v:
Vaccine: X, Vol 15, Iss , Pp 100401- (2023)
Background: The FAKHRAVAC®, an inactivated SARS-CoV-2 vaccine, was assessed for safety and immunogenicity. Methods and findings: In this double-blind, placebo-controlled, phase I trial, we randomly assigned 135 healthy adults between 18 and 55 to re
Externí odkaz:
https://doaj.org/article/c2f803c6133047028466ef7f156982f4
Autor:
Fatemeh Gholami, Ramin Hamidi Farahani, Ahmad Karimi Rahjerdi, Mohammadreza Ahi, Ali Sheidaei, Kimiya Gohari, Zahra Rahimi, Akram Ansarifar, Pouria Basiri, Milad Moradi, Arash Jahangiri, Kosar Naderi, Soheil Ghasemi, Pezhman Khatami, Mohsen Honari, Samane Khodaverdloo, Mohammad Shooshtari, Hajar Mehr Azin, Sohrab Moradi, Batool Shafaghi, Hossein Allahyari, Arina Monazah, Ali Khodaei Poor, Zahra Taghva, Hooman Bakhshande, Mohammad Karimi Nia, Masoud Solaymani Dodaran, Mohsen Forooghizade
Publikováno v:
BMC Infectious Diseases, Vol 23, Iss 1, Pp 1-9 (2023)
Abstract Background The FAKHRAVAC®, an inactivated SARS-CoV-2 vaccine, was assessed for safety and immunogenicity in a phase II trial. Methods We did a phase II, single-centered, randomized, double-blind, placebo-controlled clinical trial of the FAK
Externí odkaz:
https://doaj.org/article/7cff59226f404594bc909b45886fb632